Preparation and Characterization of Microemulsion of Cilostazol for Enhancement of Oral Bioavailability

ISSN: 1875-5704 (Online)
ISSN: 1567-2018 (Print)

Volume 14, 8 Issues, 2017

Download PDF Flyer

Current Drug Delivery

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Istvan Toth
School of Pharmacy,University of Queensland
Brisbane, 4072

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 1.446

Preparation and Characterization of Microemulsion of Cilostazol for Enhancement of Oral Bioavailability

Current Drug Delivery, 11(4): 531-540.

Author(s): Samir G. Patel, Sadhana J. Rajput, Anastasia Groshev and Vijaykumar B Sutariya.

Affiliation: Department of Pharmaceutical Sciences, University of South Florida College of Pharmacy, 12901 Bruce B. Downs Blvd., MDC 30, Tampa, FL 33612-4749, USA.


Cilostazol is a promising drug for antiplatelet combination therapy that is very important for treatment for various cardiovascular disorders. However, oral delivery of this drug is greatly impeded by the poor solubility in aqueous solutions. The aim of this study was to develop microemulsion (ME) delivery system capable of improving the drug bioavailability. In this study, Capmul MCM C8 (glycerol monocaprylate) based MEs containing Tween 20(polysorbate 20) and/or Labrafil M 1944(poly oxyglycerides) as surfactant(S) and Transcutol P(diethyl glycol monoethyl ether) as cosurfactant( CoS) were studied as potential delivery systems of cilostazol. A number of such systems were prepared containing different S:CoS ratios(1:1, 2:1 and 3:1) based on phase diagrams. Loading of cilostazol was selected as per solubilization capacity and was characterized for pH, viscosity, conductivity, particle size, zeta potential and % transmittance. The MEs systems were further investigated for chemical stability, diffusion and bioavailability. Cilostazol displayed high solubility in microemulsions with particle size up to 70 nm. It was also stable at ambient temperature up to 6 months without significant change in particle size, zeta potential, and % transmittance. Dilution up to 100 fold with aqueous medium observed a visible cloudiness having a particle size up to 104 nm. The in vitro release, and ex vivo intraduodenal diffusion, and in vivo study indicated the capacity of developed ME to improve the bioavailability (1.43 fold) via oral route administration when compared with commercially available tablets (Pletoz-50).


Cilostazol, intestinal permeability, microemulsion, oral absorption.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 11
Issue Number: 4
First Page: 531
Last Page: 540
Page Count: 10
DOI: 10.2174/1567201810666131126161957
Price: $58
14th annual Controlled Release Delivery

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science